Hodgkin's patient turns to Facebook for help
Diagnosed with Hodgkin's lymphoma at age 24, former marketing manager Pamela Bou Sejean, now 26, has undergone chemotherapy and radiation treatment to fight her disease but it has proven to be more resilient than anyone would prefer, and now the young woman requires a allogeneic stem cell transplantation.
Unfortunately, she has thus far failed to find a match, either within her family or in a worldwide search across bone marrow registries.
The problem in finding a match likely has much to do with her ethnic background: The Australian woman is of Lebanese decent.
So her brother decided to turn to social media and has launched a Facebook page to get the word out and encourage possible matches to undergo a blood test.
To find out more, you can visit their Facebook page at www.facebook.com/curepamela.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
